BioAtla Future Growth
Future criteria checks 2/6
BioAtla's earnings are forecast to decline at 6.5% per annum while its annual revenue is expected to grow at 56.9% per year. EPS is expected to grow by 11.3% per annum.
Key information
-6.5%
Earnings growth rate
11.3%
EPS growth rate
Biotechs earnings growth | 28.3% |
Revenue growth rate | 56.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
Oct 08We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate
Jul 16BioAtla: A Buried ADC Concern Gets Some New Life In 2024
May 02Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 14Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?
Nov 05We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
Jun 27Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?
Mar 24BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Sep 27BioAtla: Back From The Dead
Sep 23BioAtla: Promising Signal In NSCLC, But Concerns Remain
Aug 23BioAtla reports Q2 results
Aug 09We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate
May 11Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth
Jan 06BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans
Jul 24Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?
Mar 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 5 | -116 | -134 | N/A | 4 |
12/31/2025 | N/A | -101 | -127 | N/A | 4 |
12/31/2024 | 11 | -75 | -76 | N/A | 3 |
9/30/2024 | 11 | -82 | -85 | -85 | N/A |
6/30/2024 | N/A | -105 | -107 | -107 | N/A |
3/31/2024 | N/A | -119 | -112 | -112 | N/A |
12/31/2023 | N/A | -123 | -104 | -104 | N/A |
9/30/2023 | N/A | -124 | -99 | -98 | N/A |
6/30/2023 | N/A | -117 | -95 | -95 | N/A |
3/31/2023 | N/A | -110 | -88 | -88 | N/A |
12/31/2022 | N/A | -106 | -91 | -90 | N/A |
9/30/2022 | N/A | -102 | -87 | -87 | N/A |
6/30/2022 | N/A | -99 | -76 | -76 | N/A |
3/31/2022 | 0 | -101 | -73 | -72 | N/A |
12/31/2021 | 0 | -95 | -63 | -62 | N/A |
9/30/2021 | 0 | -79 | -57 | -55 | N/A |
6/30/2021 | 0 | -68 | -59 | -58 | N/A |
3/31/2021 | 0 | -44 | -49 | -48 | N/A |
12/31/2020 | 0 | -27 | -37 | -36 | N/A |
9/30/2020 | 3 | -22 | -25 | -24 | N/A |
12/31/2019 | 5 | -29 | -11 | -10 | N/A |
12/31/2018 | 11 | -28 | -36 | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCAB's revenue (56.9% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: BCAB's revenue (56.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCAB's Return on Equity is forecast to be high in 3 years time